SciSparc Ltd (SPRC)

[Backstabbed]

ON THE MOVE … DOWN

[gp22]

SPRC: Reverse Split news just posted...1 for 26...That is very extreme...Here is link:

Link:
https://finance.yahoo.com/news/scisparc-announces-1-26-reverse-103000478.html

[gp22]

SPRC @ $.15: Stock should selloff hard in next few days...Almost all R/S take a major hit in the few days before the Reverse....Should see sub. 10 cents in next few sessions....Best of luck and sorry for this bad situation

[Awl416]

SciSparc Ltd. Announces Pricing of $1.3 Million Underwritten Public Offering

[TrendTrade2016]

TEST THAT 90C CANDLE

[TrendTrade2016]

SPRC ON THE MOVE

[Awl416]

Margin calls

[subslover]

Currently .61 on A>H pump.

[Arnold25764]

next stop 0?

[Arnold25764]

.50, .40's or even lower next week??

[Arnold25764]

Nice drop on that good news today. Chance it will drop more?

[Awl416]

SciSparc Announces Successful Final Phase IIa Results, Meeting End Points of its Phase IIa Alzheimer Disease Patients with Agitation Trial

[Ryguy008]

Wow what a day and it's only lunch time!

$SPRC

[Mr Walnuts]

So glad I loaded this gem $SPRC

[Ryguy008]

Nice start to the week

$SPRC

[Ryguy008]

SPRC News!!! SciSparc Makes Another Step Towards Unlocking Potential Value Appoints New Strategy and Business Development VP

https://www.globenewswire.com/news-release/2023/05/30/2678385/0/en/SciSparc-Makes-Another-Step-Towards-Unlocking-Potential-Value-Appoints-New-Strategy-and-Business-Development-VP.html


$SPRC

[Mr Walnuts]

Hmmm

[Ryguy008]

SciSparc's Drug Discovery Joint Venture MitoCareX Bio Successfully Developed its Core Algorithm to allow suitable Modelling of Human Mitochondrial Carriers for Accelerating its Cancer Drug Discovery Program

https://finance.yahoo.com/news/scisparcs-drug-discovery-joint-venture-103500387.html

$SPRC

[Ryguy008]

Going green!

$SPRC

[Ryguy008]

On watch

$SPRC

[Moonboy1]

Is this being diluted? Making no sense how it's trading to me.

[subslover]

Stock is a dog with flees!!!!!!

[tw0122]

Not holding gains”As in this morning on news :SciSparc believes that the current pharmacological treatment of agitation in AD has an unsatisfactory benefit-to-risk ratio. All used drugs to treat AD are off label as evidenced by the fact that no FDA approved drug to treat agitation in AD exists. Hence, SciSparc believes the pharmacological treatment of agitation in AD is unequivocally, an unmet need.

[subslover]

Yes, this one can't hold gains very long. We can only guess what is going on. Could be dilution, maybe? This entire NASDAQ has manipulation all over it.

[Clean]

They always hit this thing so hard... Never really let it breathe... what you think it could be? Coordinated effort from big Pharma? Just pump and dumps? Because its Israeli?

As far as micro-cap biotech goes it seems to have a lot going for it. But no move ever materializes...

I don't get it...
What am I missing?

[subslover]

Nice pre-market volume.

[Mt. Blanc]

SPRC moving higher.

mb

[subslover]

SciSparc's Drug Discovery Joint Venture MitoCareX Bio Successfully Reached First Milestone for its Future Machine Learning System
February 17 2023 - 08:00AM
GlobeNewswire Inc.
Alert
Print
Share On Facebook

SciSparc Ltd. (Nasdaq: SPRC) (the “Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that its MitoCareX Bio Ltd. (“MitoCareX Bio”) joint venture , which focuses on the discovery and development of potential drugs for cancer, rare diseases and other life-threatening conditions, has achieved its first milestone pursuant to the March 10, 2022 Founders and Investment Agreement with respect to MitoCare X Bio (the “MitoCareX Bio Agreement”).
The first milestone refers to the establishment of MitoCareX Bio's cloud-based computing infrastructure that is expected to allow its future expansion into machine learning system. The system is harnessed to investigating mitochondrial carriers that are crucial for cell viability.

As a result of MitoCareX Bio meeting this milestone, SciSparc will invest an additional $400,000 in MitoCareX Bio and increase its share ownership in MitoCareX Bio from 31.48% to 41.92%.

As mitochondrial carriers hold a significant role in transporting necessary metabolites for cell functioning and survival across the inner mitochondrial membranes, the Company believes that various life-threatening conditions, such as cancer and rare diseases, might be treated by regulating the function of mitochondrial carriers. In humans, the mitochondrial carrier family (Solute Carrier Family 25, SLC25) consists of 53 members and is the largest solute transporter family.

MitoCareX Bio is currently performing virtual screening activities as well as further developing its computationally based drug discovery platform to enable its planned machine learning capabilities. MitoCareX Bio's innovative research is partly based upon successful proof-of-concept experiments previously performed in the United Kingdom.

About SciSparc Ltd. (Nasdaq: SPRC):

SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive cannabidiol (CBD): SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and status epilepticus. The Company also has a wholly-owned subsidiary whose business focusses on the sale of hemp-based products on the Amazon.com marketplace.

Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, SciSparc is using forward-looking statements when it discusses advantages and benefits of MitoCareX Bio's cloud computing and that it is expected to allow future expansion into machine learning system,that SciSparc willinvest an additional $400,000 and increase its share ownership in MitoCareX Bio from 31.48% to 41.92%, and the Company’s belief that various life-threatening conditions, such as cancer and rare diseases, might be treated by regulating the function of mitochondrial carriers. Because such statements deal with future events and are based on SciSparc's current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward- looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in SciSparc's Annual Report on Form 20-F filed with the U.S. Secu

[stock1ace1]

Sprc @.99 breakout watch here

[stock1ace1]

Yea round #2 Buying @$1.00
Here

[Runners123]

Alzheimers news and this is going to explode this afternoon

[Awl416]

News

[subslover]

SciSparc: Wellution™ Successfully Launched a New Keto Gummies Apple Cider Vinegar Product and Generated $100,000 In Revenues Within 30 Days
October 28 2022 - 07:45AM
GlobeNewswire Inc.
Alert
Print
Share On Facebook

SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that SciSparc Nutraceuticals Inc., its wholly owned subsidiary, has successfully launched a new keto gummies apple cider vinegar product under its brand Wellution™ on Amazon.com.
In the 30 days following the launch, the new product has generated more than $100,000 in revenues with an ROI (return on investment after costs of goods, marketing, advertising, shipping, storage and commissions) to the Company of approximately 117%.

"Our expansion plans for the WellutionTM brand include launching new products that will appeal to current and future customers. In the first 30 days since its launch, this new product has achieved impressive results and we are pleased with its success so far," Oz Adler, SciSparc's Chief Executive Officer, commented. "To continue expanding the Wellution’s reach, we intend to develop new attractive products, either independently or in collaboration with third parties, while reducing production and supply chain costs and exploring new markets and sales channels."

View the product at: https://www.amazon.com/Keto-Gummies-Apple-Cider-Vinegar/dp/B0B4ST8TZQ?ref_=ast_sto_dp

About SciSparc Ltd. (NASDAQ: SPRC):

SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive cannabidiol (CBD): SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and status epilepticus.

SciSparc also owns Wellution™, a brand that sells dozens of hemp-based products, including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States. Wellution™ offers eight variations of natural hemp candy supplements under two parent Amazon Standard Identification Numbers (“ASINs”) on Amazon that are differentiated by their hemp oil potency. The leading parent ASIN, which was launched in 2019, has received over 26,500 reviews and is consistently ranked as the #1 best seller in the category. In total, the brand has over 40,000 product reviews, most of which are 4 and 5-star reviews.

Forward-Looking Statements:

[Soulman856]

Going to explode here on Wednesday

[Soulman856]

Running again!

[stock1ace1]

$1.00 bust news out

[stock1ace1]

Breakout watch tomorrow :)

[stock1ace1]

Yes .77 buying here

[INFINITI]

Is it time to buy again

[subslover]

Heading in the direction of 100% land.

[PennyPusher786]

Bullish!

[PennyPusher786]

Good strength here!

[subslover]

Hey stranger, nice to see you here bro!

[abazaba375]

Nolis

[subslover]

Better watch this explosive as they are buying a food supplement company.

[kzivann]

Down after pop. Watch.


SPRC

[kzivann]

Volume 66 mil .. news sale. little flip ..watch.

SPRC

[subslover]

What a great day this turned out to be!

[subslover]

SciSparc Ltd. Announces Additional Positive Results for the Cocaine Addiction Treatment of its Psychedelic-based Pharma Collaboration with Clearmind Medicine Inc.
August 24 2022 - 07:30AM
GlobeNewswire Inc.
Alert
Print
Share On Facebook

SciSparc Ltd. (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the "Company" or "SciSparc"), today announced additional positive pre-clinical results of its Psychedelic-based Pharma Collaboration for treatment for cocaine addiction using MEAI, a novel psychedelic molecule of Clearmind Medicine Inc. (“Clearmind”) (CSE: CMND), (OTC: CMNDF), (FSE: CWY0).
These pre-clinical study results add to SciSparc’s recent announcements regarding the Company's collaboration with Clearmind for their combination treatment based on SciSparc’s CannAmide™ compound and Clearmind’s MEAI for various addictions, including pre-clinical studies results, the filing of two provisional patent applications related to compositions comprising MEAI and n-acylethanolamines and uses thereof and treating cocaine addiction.

"We are excited about these recent results in light of the potential synergistic effect between SciSparc’s CannAmide and Clearmind’s MEAI, as previously demonstrated. These results continue to indicate that we may have a targeted treatment for cocaine addiction within our reach,” commented Oz Adler, SciSparc's Chief Executive Officer. "These results reinforce our decision to enter a collaboration between the two companies."

The pre-clinical trial was led by Professor Gal Yadid and his team from the Gonda Multidisciplinary Brain Research Center located at Bar Ilan University (Ramat Gan, Israel) and was designed to evaluate the possible reward-like effects of MEAI with connection to cocaine and its ability to abolish cocaine-induced conditioned place preference.

In the pre- clinical trial, the self-administration paradigm was utilized, which is the gold-standard model for examining drug addiction and is based on operant conditioning. Rats were catheterized and trained to self-administer cocaine.

The results identified a statistically significant sub-group within the study, in a non-biased manner and high integrity, which dramatically responded to the treatment, significantly decreasing the craving for cocaine as compared to non-treated control group. This sub-group, representing 60% of animals, showed a very high response within the group.

About SciSparc Ltd. (NASDAQ:SPRC):

SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive cannabidiol (CBD): SCI-110 for the treatment of Tourette syndrome and for the treatment of Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and status epilepticus.

About Clearmind Inc. (CSE: CMND), (OTC: CMNDF), (FSE: CWY0)

Clearmind is a new biotech company focused on the discovery and development of safe and novel psychedelic-derived therapeutics to treat alcohol use disord

[kzivann]

Volume premarket.

SPRC